Christian Behrenbruch

Biography
Christian Behrenbruch, Ph.D., is Co-Founder, Managing Director, and Group Chief Executive Officer of Telix Pharmaceuticals, a global biopharmaceutical company developing diagnostic and therapeutic radiopharmaceuticals. He has more than 20 years of experience in healthcare, biotechnology, molecular imaging, and technology commercialization. Under his leadership, Telix has built an integrated radiopharmaceutical platform spanning prostate cancer imaging, targeted radiation therapy, manufacturing, and global commercialization. Dr. Behrenbruch has previously served as Chief Executive Officer of Mirada Solutions, President of CTI Molecular Imaging, and Chief Executive Officer of Fibron Technologies and ImaginAb, and he has held board and entrepreneurial roles across multiple life-science companies. He earned a D.Phil. in biomedical engineering from the University of Oxford, an MBA through TRIUM, and a law degree from the University of Melbourne, and is a Fellow of Engineers Australia. His work focuses on translating molecular targeting and radionuclide technology into scalable precision-oncology products and therapeutic platforms.